



2025年3月期 第3四半期 決算参考資料
Financial Data for the 3rd quarter of FY2025
The FY2025, the year ending March 31, 2025
April 1, 2024 - March 31, 2025

1. 連結決算概要 / Consolidated Financial Summary	2
2. セグメント別情報 / Information by Business Segment	
(1) 医療分野 / Medical Business	3,4,5
ESD (Endoscopic Solutions Division)・TSD (Therapeutic Solutions Division)	
(2) 全社消去 / Corporate Expenses	6
3. 投資他 / Expenditures etc.	6
4. 連結キャッシュフロー計算書 / Consolidated Statement of Cash Flows	6
5. 連結財政状態計算書 / Consolidated Statement of Financial Position	7
6. 会社概要 / Corporate Outline	8

(本資料における留意点について)
(Notes regarding this material)

- ・本資料のうち、業績見通し等は、現在入手可能な情報による判断および仮定に基づいたものであり、判断や仮定に内在する不確定な要素および今後の事業運営や内外の状況変化等による変動可能性に照らし、実際の業績等が目標と大きく異なる可能性があります。
- ・また、これらの情報は、今後予告なしに変更されることがあります。従いまして、本情報及び資料の利用は、他の方法により入手された情報とも照合確認し、利用者の判断によって行ってくださいようお願い致します。
- ・本資料利用の結果生じたいかなる損害についても、当社は一切責任を負いません。
- ・2023年4月に非継続事業（エビデント）の全株式の譲渡が完了したことに伴い、本株式譲渡に係る譲渡益を2024年3月期第1四半期連結会計期間に計上しています。
- ・整形外科事業の譲渡に関する正式契約の締結に伴い、2025年3月期第1四半期連結会計期間より、整形外科事業を非継続事業に分類しています。これに伴い、過去に開示した以下の数値も組み替えて表示しています。**尚、本資料は、監査法人による監査又はレビューの対象には含まれておりません。**

連結損益計算書：「2024年3月期第1四半期（3カ月）、第2四半期（3カ月）、第3四半期（3カ月）、第4四半期（3カ月）、通期」
連結キャッシュフロー計算書：「2024年3月期第1四半期（3カ月）、第2四半期（3カ月）、第3四半期（3カ月）、第4四半期（3カ月）、通期」

- ・This material contains forward-looking statements that reflect management's current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Company's actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements.
 - ・Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions.
 - ・Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.
 - ・Since all shares of discontinued operation (Evident) were transferred in April 2023, a gain on this share transfer was recorded in FY2024Q1.
 - ・Following the conclusion of definitive agreement for divestiture of Orthopedic Business, Orthopedic Business is categorized as a discontinued operation, effective Q1 of FY2025. Accordingly, figures for below accounting periods are restated. **This material is not subject to audit or review by an auditor.**
- Consolidated Statements of Profit or Loss: FY2024.Q1 (3M), FY2024.Q2 (3M), FY2024.Q3 (3M), FY2024.Q4 (3M), FY2024 (total)
Consolidated Statement of cash flows: FY2024.Q1 (3M), FY2024.Q2 (3M), FY2024.Q3 (3M), FY2024.Q4 (3M), FY2024 (total)

1. 連結決算概要 / Consolidated Financial Summary

■ 連結損益計算書概要 / Summary of Consolidated Statements of Profit or Loss

百万円 (¥ million)	FY2024						FY2025				Total forecast	FY2025 As of Nov 8 forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total		
売上高 Revenue	204,985	226,608	236,504	668,097	257,655	925,752	234,821	239,208	251,192	725,221	997,500	1,009,000
売上原価 Cost of sales	69,416	76,947	75,055	221,418	85,902	307,320	78,615	72,458	83,213	234,286	324,500	318,000
売上総利益 Gross profit	135,569	149,661	161,449	446,679	171,753	618,432	156,206	166,750	167,979	490,935	673,000	691,000
販売費及び一般管理費 S.G.A. expenses	107,101	111,380	117,697	336,178	130,580	466,758	118,833	119,074	125,069	362,976	499,000	494,000
その他の収益および費用等 Other income and expenses etc.	-5,842	-57,140	-9,534	-72,516	-27,771	-100,287	-9,896	-4,623	-4,645	-19,164	-23,000	-21,000
営業利益 Operating profit	22,626	-18,859	34,218	37,985	13,402	51,387	27,477	43,053	38,265	108,795	151,000	176,000
調整後営業利益 Adjusted operating profit	28,279	38,236	43,632	110,147	41,169	151,316	37,236	47,832	43,129	128,197	174,500	197,500
金融収益および費用 Finance income and costs	-2,790	-3,028	-184	-6,002	-1,774	-7,776	-1,079	-646	-1,854	-3,579	-5,000	-6,000
税引前利益 Profit before tax	19,836	-21,887	34,034	31,983	11,628	43,611	26,398	42,407	36,411	105,216	146,000	170,000
法人所得税費用 Income taxes	6,270	3,947	14,868	25,085	-16,539	8,546	11,612	7,930	9,317	28,859	41,000	50,000
当期利益(損失) Profit (loss)	240,614	-23,955	18,916	235,575	7,354	242,929	14,583	34,395	27,406	76,384	105,000	121,000
親会社の所有者に帰属する当期利益(損失) Profit (loss) attributable to owners of parent	240,560	-24,264	18,916	235,212	7,354	242,566	14,583	34,395	27,406	76,384	105,000	121,000
売上総利益率 Gross profit ratio	66.1%	66.0%	68.3%	66.9%	66.7%	66.8%	66.5%	69.7%	66.9%	67.7%	67.5%	68.5%
販管費率 S.G.A. ratio	52.3%	49.2%	49.8%	50.3%	50.7%	50.4%	50.6%	49.8%	49.8%	50.1%	50.0%	49.0%
営業利益率 Operating profit margin	11.0%	-	14.5%	5.7%	5.2%	5.6%	11.7%	18.0%	15.2%	15.0%	15.1%	17.4%
調整後営業利益率 Adjusted operating margin	13.8%	16.9%	18.4%	16.5%	16.0%	16.3%	15.9%	20.0%	17.2%	17.7%	17.5%	19.6%
EBITDA	39,056	-2,769	50,276	86,563	30,017	116,580	44,553	58,959	54,395	157,907	217,500	243,500
EBITDAマージン EBITDA margin	19.1%	-	21.3%	13.0%	11.7%	12.6%	19.0%	24.6%	21.7%	21.8%	21.8%	24.1%

*「その他の収益および費用等」は、持分法による投資損益・その他の収益・その他の費用の合算です。

"Other income and expenses etc." in the above table is the sum of share of profit (loss) of investments accounted for using equity method, other income, and other expenses.

*2023年4月に非継続事業（エビデント）の全株式の譲渡が完了したことに伴い、本株式譲渡に係る譲渡益をFY2024Q1に計上しています。

Since all shares of discontinued operation (Evident) were transferred in April 2023, a gain on this share transfer was recorded in FY2024Q1.

*FY2025Q1より整形外科事業を非継続事業に分類しています。非継続事業からの利益は継続事業と区分し、「売上高」から「法人所得税費用」までは継続事業の金額を表示しています。

From FY2025Q1, Orthopedic Business has been reclassified as a discontinued operation. Accordingly, profit from discontinued operation is presented separately from the profit from continuing operations. From "revenue" to "Income taxes" in the above table are amounts related to continuing operations only.

■ 為替 / Foreign exchange

円 (¥)	FY2024						FY2025				Total forecast	FY2025 As of Nov 8 forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total		
円/USD (期中平均レート) Yen/U.S. dollar (Average rate)	137.37	144.62	147.89	143.29	148.61	144.62	155.88	149.38	152.44	152.57	153.68	151.00
円/EUR (期中平均レート) Yen/Euro (Average rate)	149.47	157.30	159.11	155.29	161.31	156.80	167.88	164.01	162.59	164.83	164.37	163.00
円/CNY (期中平均レート) Yen/Renminyuan (Average rate)	19.56	19.94	20.44	19.98	20.63	20.14	21.48	20.82	21.16	21.15	21.11	21.00

百万円 (¥ million)	FY2024						FY2025			
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 Total	
売上高に対する為替影響額 FX Impact on revenue	8,172	9,460	10,882	28,514	22,279	50,793	22,717	7,630	6,120	36,467
営業利益に対する為替影響額 FX Impact on operating profit	4,562	-1,116	3,457	6,903	5,409	12,312	4,414	10,822	1,655	16,891

*上表の数値は継続事業の金額を表示しています。 / Amounts in the above table are related to continuing operations only.

■ 為替感応度（年間） / Foreign exchange sensitivity (Annual basis)

億円 (¥ 100 million)	売上高 Revenue		営業利益 Operating profit	
	2024	2025	2024	2025
ドル (1円あたり) U.S. dollar (Per 1JPY)	26	26	5	5
ユーロ (1円あたり) Euro (Per 1JPY)	16	16	5	5
人民元 (1円あたり) Renminyuan (Per 1JPY)	52	52	27	27

*上表の数値は継続事業の金額を表示しています。 / Amounts in the above table are related to continuing operations only.

*上表の数値はFY2024Q4実績より算出しています。 / Amounts in the above table are calculated based on FY2024Q4 results.

2. セグメント別情報 / Information by Business Segment

(1) 医療分野 / Medical Business

■ ESD 損益 / Revenue and Operating profit of ESD

百万円 (¥ million)	FY2024						FY2025					FY2025 As of Nov 8 forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Total forecast	
売上高 Revenue	127,138	143,729	148,449	419,316	167,301	586,617	147,387	151,319	160,821	459,527	634,000	645,000
営業利益 Operating profit	22,177	28,732	32,671	83,580	21,104	104,684	27,374	35,180	31,339	93,893	137,500	162,000
その他の損益 Other income and expenses	-3,390	-4,423	-4,133	-11,946	-16,473	-28,419	-5,188	-3,727	-3,954	-12,869	-14,000	-12,500
調整後営業利益 Adjusted operating profit	25,567	33,155	36,804	95,526	37,577	133,103	32,562	38,907	35,293	106,762	151,500	174,500
営業利益率 Operating profit margin	17.4%	20.0%	22.0%	19.9%	12.6%	17.8%	18.6%	23.2%	19.5%	20.4%	21.7%	25.1%
調整後営業利益率 Adjusted operating margin	20.1%	23.1%	24.8%	22.8%	22.5%	22.7%	22.1%	25.7%	21.9%	23.2%	23.9%	27.1%
売上高対前年比 Revenue (YoY)							15.9%	5.3%	8.3%	9.6%	8.1%	10.0%
営業利益対前年比 Operating profit (YoY)							23.4%	22.4%	-4.1%	12.3%	31.3%	54.8%

■ TSD 損益 / Revenue and Operating profit of TSD

百万円 (¥ million)	FY2024						FY2025					FY2025 As of Nov 8 forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Total forecast	
売上高 Revenue	77,156	82,542	87,528	247,226	90,105	337,331	87,284	87,754	90,304	265,342	363,000	363,000
営業損益 Operating profit (loss)	9,681	-38,223	12,366	-16,176	7,710	-8,466	10,271	16,575	15,501	42,347	54,500	54,500
その他の損益 Other income and expenses	-1,899	-52,765	-3,831	-58,495	-6,994	-65,489	-3,669	-2,156	-1,776	-7,601	-8,500	-7,500
調整後営業利益 Adjusted operating profit	11,580	14,542	16,197	42,319	14,704	57,023	13,940	18,731	17,277	49,948	63,000	62,000
営業利益率 Operating profit margin	12.5%	-	14.1%	-	8.6%	-	11.8%	18.9%	17.2%	16.0%	15.0%	15.0%
調整後営業利益率 Adjusted operating margin	15.0%	17.6%	18.5%	17.1%	16.3%	16.9%	16.0%	21.3%	19.1%	18.8%	17.4%	17.1%
売上高対前年比 Revenue (YoY)							13.1%	6.3%	3.2%	7.3%	7.6%	7.6%
営業利益対前年比 Operating profit (YoY)							6.1%	-	25.4%	-	-	-

■ 医療分野 損益 / Revenue and Operating profit of Medical Business

百万円 (¥ million)	FY2024						FY2025					FY2025 As of Nov 8 forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Total forecast	
売上高 Revenue	204,294	226,271	235,977	666,542	257,406	923,948	234,671	239,073	251,125	724,869	997,000	1,008,000
営業利益 Operating profit	31,858	-9,491	45,037	67,404	28,814	96,218	37,645	51,755	46,840	136,240	192,000	216,500
その他の損益 Other income and expenses	-5,289	-57,188	-7,964	-70,441	-23,467	-93,908	-8,857	-5,883	-5,730	-20,470	-22,500	-20,000
調整後営業利益 Adjusted operating profit	37,147	47,697	53,001	137,845	52,281	190,126	46,502	57,638	52,570	156,710	214,500	236,500
営業利益率 Operating profit margin	15.6%	-	19.1%	10.1%	11.2%	10.4%	16.0%	21.6%	18.7%	18.8%	19.3%	21.5%
調整後営業利益率 Adjusted operating margin	18.2%	21.1%	22.5%	20.7%	20.3%	20.6%	19.8%	24.1%	20.9%	21.6%	21.5%	23.5%
売上高対前年比 Revenue (YoY)							14.9%	5.7%	6.4%	8.8%	7.9%	9.1%
営業利益対前年比 Operating profit (YoY)							18.2%	-	4.0%	102.1%	99.5%	125.0%

■ ESD 地域別売上高 / Revenue by Region of ESD

百万円 (¥ million)	FY2024						FY2025			
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
日本 Japan	16,142	18,589	16,242	50,973	20,919	71,892	15,714	17,098	16,710	49,522
北米 North America	45,822	50,968	54,534	151,324	65,241	216,565	62,856	60,432	65,715	189,003
欧州 Europe	31,070	31,581	39,244	101,897	44,036	145,931	35,343	33,684	40,631	109,661
中国 China	17,415	23,391	18,673	59,479	15,471	74,950	15,535	17,949	15,964	49,448
アジア・オセアニア Asia and Oceania	13,389	14,899	14,100	42,388	16,591	58,979	13,509	16,750	16,050	46,309
その他 Other	3,300	4,302	5,655	13,255	5,043	18,300	4,430	5,406	5,751	15,584
合計 Total	127,138	143,730	148,448	419,316	167,301	586,617	147,387	151,319	160,821	459,527

■ TSD 地域別売上高 / Revenue by Region of TSD

百万円 (¥ million)	FY2024						FY2025			
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
日本 Japan	10,925	10,988	12,249	34,162	10,333	44,495	9,453	9,941	10,343	29,737
北米 North America	30,351	32,892	34,504	97,747	36,919	134,666	37,670	37,734	38,684	114,088
欧州 Europe	20,498	20,516	23,604	64,617	26,095	90,714	24,399	22,138	24,374	70,910
中国 China	7,010	8,935	7,178	23,123	7,625	30,748	6,713	7,610	6,191	20,514
アジア・オセアニア Asia and Oceania	6,805	7,355	7,554	21,714	7,183	28,897	7,104	8,159	8,355	23,618
その他 Other	1,567	1,856	2,439	5,863	1,950	7,811	1,945	2,172	2,357	6,475
合計 Total	77,156	82,542	87,528	247,226	90,105	337,331	87,284	87,754	90,304	265,342

■ 医療分野 地域別売上高 / Revenue by Region of Medical Business

百万円 (¥ million)	FY2024						FY2025			
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
日本 Japan	27,067	29,577	28,491	85,135	31,252	116,387	25,167	27,039	27,053	79,259
北米 North America	76,173	83,860	89,038	249,071	102,160	351,231	100,526	98,166	104,399	303,091
欧州 Europe	51,568	52,097	62,848	166,514	70,131	236,645	59,742	55,822	65,005	180,570
中国 China	24,425	32,326	25,851	82,602	23,096	105,698	22,248	25,559	22,155	69,962
アジア・オセアニア Asia and Oceania	20,194	22,254	21,654	64,102	23,774	87,876	20,613	24,909	24,405	69,927
その他 Other	4,867	6,158	8,094	19,118	6,993	26,111	6,375	7,578	8,108	22,060
合計 Total	204,294	226,272	235,976	666,542	257,406	923,948	234,671	239,073	251,125	724,869

■ サブセグメント別売上占有率 / Sub-segment Sales Ratio

	YTD	
ESD		
消化器内視鏡 GI Endoscopy	約 Approx.	55 %
外科内視鏡 Surgical Endoscopy	約 Approx.	10 %
医療サービス Medical Service	約 Approx.	35 %
TSD		
消化器科処置具 GI EndoTherapy	約 Approx.	30 %
泌尿器科 Urology	約 Approx.	35 %
呼吸器科 Respiratory	約 Approx.	15 %
その他の治療領域 Other Therapeutic Areas	約 Approx.	20 %

* 四捨五入のため、合計値が100%にならないことがあります。/ Due to rounding, the total may not add up to 100%.

■地域別成長率（為替影響調整後） /

Growth Rate by Region (After Foreign Exchange Adjustment)

		FY2024						FY2025			
		Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
ESD	日本	8%	3%	6%	6%	-6%	2%	-3%	-8%	3%	-3%
	Japan	8%	3%	6%	6%	-6%	2%	-3%	-8%	3%	-3%
	北米	3%	0%	7%	3%	26%	9%	37%	19%	21%	25%
	North America	-3%	-4%	3%	-1%	13%	2%	21%	15%	17%	17%
	欧州	0%	2%	12%	5%	18%	9%	14%	7%	4%	8%
	Europe	-6%	-7%	4%	-3%	5%	-0%	2%	2%	0%	1%
	中国	41%	-3%	-17%	1%	-35%	-10%	-11%	-23%	-15%	-17%
	China	40%	-2%	-20%	0%	-40%	-12%	-20%	-27%	-18%	-22%
	アジア・オセアニア	20%	11%	7%	12%	18%	14%	1%	12%	14%	9%
	Asia and Oceania	18%	7%	2%	8%	10%	9%	-7%	9%	12%	5%
	分野計	9%	1%	6%	5%	9%	6%	16%	5%	8%	10%
Total	5%	-3%	1%	1%	0%	1%	5%	2%	6%	4%	
TSD	日本	1%	-6%	5%	0%	-14%	-4%	-13%	-10%	-16%	-13%
	Japan	1%	-6%	5%	0%	-14%	-4%	-13%	-10%	-16%	-13%
	北米	6%	4%	7%	6%	17%	9%	24%	15%	12%	17%
	North America	0%	0%	3%	1%	5%	2%	9%	11%	9%	10%
	欧州	6%	9%	9%	8%	15%	10%	19%	8%	3%	10%
	Europe	-1%	-2%	1%	0%	3%	1%	6%	3%	1%	3%
	中国	3%	-12%	-4%	-5%	-21%	-10%	-4%	-15%	-14%	-11%
	China	2%	-11%	-7%	-6%	-27%	-12%	-14%	-19%	-17%	-17%
	アジア・オセアニア	24%	8%	16%	15%	7%	13%	4%	11%	11%	9%
	Asia and Oceania	23%	4%	10%	12%	-0%	8%	-4%	8%	9%	5%
	分野計	7%	2%	8%	6%	7%	6%	13%	6%	3%	7%
Total	2%	-2%	3%	1%	-3%	0%	2%	3%	1%	2%	
医療分野	日本	5%	0%	5%	3%	-9%	-0%	-7%	-9%	-5%	-7%
Medical Business	Japan	5%	0%	5%	3%	-9%	-0%	-7%	-9%	-5%	-7%
	北米	4%	2%	7%	4%	23%	9%	32%	17%	17%	22%
	North America	-1%	-3%	3%	0%	10%	2%	16%	13%	14%	14%
	欧州	3%	4%	11%	6%	17%	9%	16%	7%	3%	8%
	Europe	-4%	-5%	3%	-2%	5%	0%	4%	3%	0%	2%
	中国	27%	-6%	-14%	-1%	-31%	-10%	-9%	-21%	-14%	-15%
	China	27%	-5%	-17%	-2%	-37%	-12%	-18%	-25%	-17%	-20%
	アジア・オセアニア	21%	10%	10%	13%	14%	13%	2%	12%	13%	9%
	Asia and Oceania	19%	6%	5%	9%	7%	9%	-6%	8%	11%	5%
	分野計	8%	2%	7%	5%	9%	6%	15%	6%	6%	9%
Total	4%	-2%	2%	1%	-1%	0%	4%	2%	4%	3%	

*下線部は為替影響調整後の成長率です。 / Underlined part :Growth rate after foreign exchange adjustment

■サブセグメント別成長率（為替影響調整後） /

Growth Rate by Sub-segment (After Foreign Exchange Adjustment)

		FY2024						FY2025			
		Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
ESD	消化器内視鏡	3%	-5%	1%	0%	9%	2%	15%	4%	10%	9%
	GI Endoscopy	0%	-8%	-3%	-4%	0%	-3%	4%	1%	7%	4%
	外科内視鏡	24%	-2%	6%	8%	-10%	2%	7%	5%	2%	5%
	Surgical Endoscopy	19%	-5%	1%	4%	-16%	-3%	-2%	1%	0%	0%
	医療サービス	13%	14%	14%	14%	21%	16%	21%	8%	8%	12%
	Medical Service	8%	8%	8%	8%	10%	8%	8%	4%	5%	6%
	分野計	9%	1%	6%	5%	9%	6%	16%	5%	8%	10%
Total	5%	-3%	1%	1%	0%	1%	5%	2%	6%	4%	
TSD	消化器科処置器具	9%	11%	14%	11%	14%	12%	15%	6%	1%	7%
	GI EndoTherapy	5%	6%	9%	7%	5%	6%	5%	3%	-1%	2%
	泌尿器科	8%	1%	3%	4%	13%	6%	18%	10%	11%	13%
	Urology	2%	-4%	-2%	-2%	2%	-1%	5%	6%	8%	6%
	呼吸器科	2%	2%	2%	2%	5%	3%	24%	5%	15%	14%
	Respiratory	-2%	-2%	-3%	-2%	-5%	-3%	11%	1%	12%	8%
	その他の治療領域	5%	-5%	12%	4%	-8%	1%	-4%	2%	-12%	-5%
	Other Therapeutic Areas	1%	-9%	7%	0%	-16%	-5%	-13%	-1%	-14%	-10%
	分野計	7%	2%	8%	6%	7%	6%	13%	6%	3%	7%
Total	2%	-2%	3%	1%	-3%	0%	2%	3%	1%	2%	

*下線部は為替影響調整後の成長率です。 / Underlined part :Growth rate after foreign exchange adjustment

2. セグメント別情報 / Information by Business Segment

(2) 全社消去 / Corporate expenses

■損益 / Revenue and Operating profit

百万円 (¥ million)	FY2024						FY2025				FY2025 As of Nov 8 forecast	
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total		Total forecast
売上高 Revenue	-	-	-	-	-	-	-	-	-	-	-	-
営業損益 Operating profit (loss)	-9,266	-9,343	-10,855	-29,464	-15,080	-44,544	-9,937	-8,546	-8,417	-26,900	-40,000	-40,500
その他の損益 Other income and expenses	-358	70	-1,456	-1,744	-4,166	-5,910	-925	1,104	834	1,013	-1,000	-1,500

* FY2025Q1より整形外科事業を非継続事業に分類したことに伴い、FY2024Q1、Q2、Q3、Q4、totalの数値も組み替えて表示しています。

From FY2025Q1, Orthopedic Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2024Q1, Q2, Q3, Q4, and total.

3. 投資他 / Expenditures etc

■連結 / Consolidated

百万円 (¥ million)	FY2024						FY2025				FY2025 As of Nov 8 forecast	
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total		Total forecast
減価償却費 Depreciation and amortization	16,430	16,090	16,058	48,578	16,615	65,193	17,076	15,906	16,130	49,112	66,500	67,500
資本的支出 Capital expenditures	18,625	15,028	19,244	52,897	26,446	79,343	18,473	17,248	17,847	53,568	81,000	89,000
研究開発支出 R&D expenditures	17,647	20,679	21,932	60,258	25,084	85,342	24,010	19,196	26,982	70,188	96,000	96,000
開発費資産化 Capitalization of R&D expenditures	2,569	3,438	3,896	9,903	5,169	15,072	3,102	3,842	3,243	10,187	14,500	17,500

* 上表の数値は継続事業の金額を表示しています。 / Amounts in the above table are related to continuing operations only.

■ESD

百万円 (¥ million)	FY2024						FY2025			
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
減価償却費 Depreciation and amortization	10,276	10,261	10,361	30,898	10,603	41,501	11,417	10,021	10,762	32,200
資本的支出 Capital expenditures	11,821	10,196	12,960	34,977	15,697	50,674	11,834	12,318	11,705	35,857
研究開発支出 R&D expenditures	10,178	12,635	13,490	36,303	15,721	52,024	14,844	11,986	19,167	45,997

■TSD

百万円 (¥ million)	FY2024						FY2025			
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
減価償却費 Depreciation and amortization	4,683	4,551	4,347	13,581	4,603	18,184	4,623	4,553	4,666	13,842
資本的支出 Capital expenditures	3,721	4,373	4,179	12,273	7,022	19,295	5,637	3,817	4,807	14,261
研究開発支出 R&D expenditures	5,635	6,270	6,804	18,709	7,180	25,889	8,209	6,252	6,878	21,339

■医療分野 / Medical Business

百万円 (¥ million)	FY2024						FY2025			
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
減価償却費 Depreciation and amortization	14,959	14,812	14,708	44,479	15,206	59,685	16,040	14,574	15,428	46,042
資本的支出 Capital expenditures	15,542	14,569	17,139	47,250	22,719	69,969	17,471	16,135	16,512	50,118
研究開発支出 R&D expenditures	15,813	18,905	20,294	55,012	22,901	77,913	23,053	18,238	26,045	67,336

■その他・全社消去 / Other, Corporate expenses

百万円 (¥ million)	FY2024						FY2025			
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
減価償却費 Depreciation and amortization	1,471	1,278	1,350	4,099	1,409	5,508	1,036	1,332	702	3,070
資本的支出 Capital expenditures	3,083	459	2,105	5,647	3,727	9,374	1,002	1,113	1,335	3,450
研究開発支出 R&D expenditures	1,834	1,774	1,638	5,246	2,183	7,429	957	958	937	2,852

* FY2025Q1より整形外科事業を非継続事業に分類したことに伴い、FY2024Q1、Q2、Q3、Q4、totalの数値も組み替えて表示しています。

From FY2025Q1, Orthopedic Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2024Q1, Q2, Q3, Q4, and total.

4. 連結キャッシュ・フロー計算書 / Consolidated statement of cash flows

百万円 (¥ million)	FY2024						FY2025			
	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q3 Total
営業キャッシュ・フロー Cash flows from operating activities	-53,112	41,335	-1,084	-12,861	55,226	42,365	23,257	70,455	32,587	126,299
投資キャッシュ・フロー Cash flows from investing activities	426,988	-14,287	-21,256	391,445	-31,453	359,992	-15,160	-14,863	-12,534	-42,557
フリー・キャッシュ・フロー Free cash flow	373,876	27,048	-22,340	378,584	23,773	402,357	8,097	55,592	20,053	83,742
調整後フリー・キャッシュ・フロー Adjusted Free cash flow	-10,266	27,961	13,303	30,998	39,907	70,905	14,764	24,504	24,090	63,358
財務キャッシュ・フロー Cash flows from financing activities	-25,888	-99,534	-115,363	-240,785	-35,225	-276,010	-77,478	-79,263	-49,847	-206,588

*調整後フリー・キャッシュ・フローの主な特殊要因はプレゼンテーションを参照ください。 / Please refer to the presentation for the major adjusted items of adjusted free cash flow.

5. 連結財政状態計算書 / Consolidated statement of financial position

百万円 (¥ million)	FY2024				FY2025			
	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31
資産 Assets	1,688,272	1,617,765	1,468,078	1,534,216	1,515,386	1,366,645	1,406,931	-
流動資産 Current assets	964,843	921,789	788,140	800,340	736,623	657,065	647,390	-
現金及び現金同等物 Cash and cash equivalents	558,722	488,160	348,572	340,933	274,408	245,869	220,257	-
棚卸資産 Inventories	177,487	183,430	186,517	190,030	190,395	187,843	197,102	-
売却目的で保有する資産 Assets held for sale	565	-	-	55	12,535	55	-	-
その他 Other	228,069	250,199	253,051	269,322	259,285	223,298	230,031	-
非流動資産 Non-current assets	723,429	695,976	679,938	733,876	778,763	709,580	759,541	-
負債 Liabilities	781,348	790,233	718,196	777,030	725,328	663,553	672,271	-
流動負債 Current liabilities	416,394	423,282	379,955	431,695	419,194	419,575	414,555	-
売却目的で保有する資産に直接関連する負債 Liabilities directly associated with assets held for sale	28	-	-	-	4,030	-	-	-
非流動負債 Non-current liabilities	364,954	366,951	338,241	345,335	306,134	243,978	257,716	-
資本 Equity	906,924	827,532	749,882	757,186	790,058	703,092	734,660	-
親会社の所有者に帰属する持分 Total equity attributable to owners of parent	905,904	827,532	749,882	757,186	790,058	703,092	734,660	-
その他 Other	1,020	-	-	-	-	-	-	-
有利子負債 Interest-bearing debt	345,966	348,414	304,679	299,616	254,554	245,482	233,333	-
純有利子負債 Net debt	-212,756	-139,746	-43,893	-41,317	-19,854	-387	13,076	-
自己資本比率 Equity ratio	53.7%	51.2%	51.1%	49.4%	52.1%	51.4%	52.2%	-
有利子負債比率 Interest-bearing debt ratio	38.2%	42.1%	40.6%	39.6%	32.2%	34.9%	31.8%	-

6. 会社概要 / Corporate Outline

■ 会社概要 / Corporate outline

2024年9月30日現在
As of Sep 30, 2024

会社名 Company name	オリンパス株式会社 Olympus Corporation
上場市場 Market	東京証券取引所プライム市場 Prime Market
銘柄コード Stock code	7733 ISIN: JP3201200007
設立年月日 Established	1919年10月12日 October 12, 1919
資本金 (百万円) Capital (¥ million)	124,643
グループ会社数 Number of group companies	85 (本社除く / excluding Olympus Corporation)
本社 Head Office	〒192-8507 東京都八王子市石川町2951 https://www.olympus.co.jp/ 2951 Ishikawa-machi, Hachioji-shi, Tokyo 192-8507, Japan https://www.olympus-global.com/network/
事業場 Factory, R&D Center	八王子市 (東京都)、上伊那郡 (長野県)、西白河郡 (福島県) Hachioji Tokyo Met., Kami Ina Nagano Pref., Nishi Shirakawa Fukushima Pref.
支店 Branch Offices	札幌、名古屋、大阪、広島、福岡、神戸 Sapporo, Nagoya, Osaka, Hiroshima, Fukuoka, Kobe
営業所 Sales Offices	新潟、松本、静岡、金沢、京都、岡山、松山、鹿児島 Niigata, Matsumoto, Shizuoka, Kanazawa, Kyoto, Okayama, Matsuyama, Kagoshima
海外拠点 Overseas Offices	アメリカ、ドイツ、イギリス、中国、シンガポールほか USA, Germany, UK, China, Singapore etc

■ 株式状況 / Stock information

2024年9月30日現在
As of Sep 30, 2024

発行可能株式総数 (株) Total Number of Authorized Shares (Shares)	4,000,000,000
発行済株式総数 (株) Number of Shares Issued (Shares)	1,177,700,200

■ 株式の分布状況 / Shareholder Distribution

2024年9月30日現在
As of Sep 30, 2024

	所有株式数 Number of shares	所有株式数の割合 Shareholders ratio
金融機関 Japanese financial institution	405,053,992	34.4%
証券会社 Japanese securities firms	15,459,333	1.3%
その他国内法人 Other Japanese corporations	23,055,254	2.0%
外国人 Foreign institutions and individuals	646,077,049	54.9%
個人・その他 Jananese individuals and other	54,314,936	4.6%
自己株式 Treasury stock	33,739,636	2.9%
合計 Total	1,177,700,200	100.0%

■ 従業員数 / Number of employees

	FY2024		FY2025							
	As of Mar 31		As of Jun 30		As of Sep 30		As of Dec 31		As of Mar 31	
合計 Total	28,501	(17,357)	28,665	(17,323)	28,692	(17,498)	29,163	(18,014)		
内視鏡事業 Endoscopic Solutions Division	14,948	(8,361)	15,735	(8,408)	15,718	(8,462)	16,148	(8,824)		
治療機器事業 Therapeutic Solutions Division	8,337	(6,000)	8,041	(5,848)	7,961	(5,800)	8,210	(6,060)		
医療分野 Medical Business	23,285	(14,361)	23,776	(14,256)	23,679	(14,262)	24,358	(14,884)		
その他、全社 Other, Corporate	5,216	(2,996)	4,889	(3,067)	5,013	(3,236)	4,805	(3,130)		

* () は海外従業員数です。 / () : Number of overseas employees

* FY2025Q1より整形外科事業を非継続事業に分類したことに伴い、FY2024Q4の数値も組み替えて表示しています。

From FY2025Q1, Orthopedic Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2024Q4.